Literature DB >> 24395443

Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment.

Christine Reinemann1, Beate Strehlitz.   

Abstract

Aptamers are single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) oligonucleotides, which are able to bind their target with high selectivity and affinity. Owing to their multiple talents, aptamers combined with nanoparticles are nanosystems well qualified for the development of new biomedical devices for analytical, imaging, drug delivery and many other medical applications. Because of their target affinity, aptamers can direct the transport of aptamer-nanoparticle conjugates. The binding of the aptamers to the target "anchors" the nanoparticle-aptamer conjugates at their site of action. In this way, nanoparticle-based bioimaging and smart drug delivery are enabled, especially by use of systematically developed aptamers for cancer-associated biomarkers. This review article gives a brief overview of recent relevant research into aptamers and trends in their use in cancer diagnostics and therapy. A concise description of aptamers, their development and functionalities relating to nanoparticle modification is given. The main part of the article is dedicated to current developments of aptamer-modified nanoparticles and their use in cancer diagnostics and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395443     DOI: 10.4414/smw.2014.13908

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  11 in total

Review 1.  Strategies to develop endogenous stem cell-recruiting bioactive materials for tissue repair and regeneration.

Authors:  Settimio Pacelli; Sayantani Basu; Jonathan Whitlow; Aparna Chakravarti; Francisca Acosta; Arushi Varshney; Saman Modaresi; Cory Berkland; Arghya Paul
Journal:  Adv Drug Deliv Rev       Date:  2017-07-19       Impact factor: 15.470

Review 2.  Aptamer selection and applications for breast cancer diagnostics and therapy.

Authors:  Mei Liu; Xiaocheng Yu; Zhu Chen; Tong Yang; Dandan Yang; Qianqian Liu; Keke Du; Bo Li; Zhifei Wang; Song Li; Yan Deng; Nongyue He
Journal:  J Nanobiotechnology       Date:  2017-11-13       Impact factor: 10.435

Review 3.  Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.

Authors:  Joy Sebastian Prakash; Karunanithi Rajamanickam
Journal:  Biomedicines       Date:  2015-09-01

4.  Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.

Authors:  Xiaomei Yang; Jing Zhao; Siliang Duan; Xiaoqiong Hou; Xi Li; Zixi Hu; Zhuoran Tang; Fengzhen Mo; Xiaoling Lu
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

Review 5.  Fitness Landscapes of Functional RNAs.

Authors:  Ádám Kun; Eörs Szathmáry
Journal:  Life (Basel)       Date:  2015-08-21

6.  Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2014-06-17       Impact factor: 10.183

7.  Preparation and Characterization of Novel Perfluorooctyl Bromide Nanoparticle as Ultrasound Contrast Agent via Layer-by-Layer Self-Assembly for Folate-Receptor-Mediated Tumor Imaging.

Authors:  Yue Hu; Yong Wang; Jianshuai Jiang; Baosan Han; Shengmin Zhang; Keshi Li; ShuXiong Ge; Yahui Liu
Journal:  Biomed Res Int       Date:  2016-08-29       Impact factor: 3.411

Review 8.  Linking aptamer-ligand binding and expression platform folding in riboswitches: prospects for mechanistic modeling and design.

Authors:  Fareed Aboul-ela; Wei Huang; Maaly Abd Elrahman; Vamsi Boyapati; Pan Li
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-09-11       Impact factor: 9.957

9.  Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects.

Authors:  Wei Tao; Xiaowei Zeng; Jun Wu; Xi Zhu; Xinghua Yu; Xudong Zhang; Jinxie Zhang; Gan Liu; Lin Mei
Journal:  Theranostics       Date:  2016-02-11       Impact factor: 11.556

Review 10.  Aptamer-iRNAs as Therapeutics for Cancer Treatment.

Authors:  Mario M Soldevilla; Daniel Meraviglia-Crivelli de Caso; Ashwathi P Menon; Fernando Pastor
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.